Xylotin 50mg Injection contains Oxaliplatin, a platinum-based chemotherapeutic agent used primarily in the treatment of colorectal cancer. Oxaliplatin exerts its antineoplastic effects by forming platinum-DNA adducts, leading to inhibition of DNA replication and transcription, ultimately inducing apoptosis in rapidly dividing cancer cells. Xylotin 50mg is administered intravenously, typically as part of combination chemotherapy regimens such as FOLFOX, which includes fluorouracil and leucovorin. The dosage and treatment schedule should be individualized based on the patient’s clinical condition, tumor response, and tolerability. Common adverse effects associated with Oxaliplatin include peripheral neuropathy, myelosuppression, gastrointestinal disturbances such as nausea and diarrhea, and hypersensitivity reactions. It is contraindicated in patients with a known hypersensitivity to platinum compounds. Caution is advised in patients with pre-existing neuropathy, hepatic impairment, or renal dysfunction. Regular monitoring of blood counts, renal and hepatic function, and neurological status is recommended during therapy. Xylotin 50mg Injection should be administered under the supervision of an experienced oncologist in a healthcare setting equipped to manage potential infusion-related reactions. Proper handling and disposal procedures must be followed due to the cytotoxic nature of Oxaliplatin.